A Phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL antibody drug conjugate
Anti-Tumor Efficacy of BA3021
Potent CAB PD-1 Abs to Reduce Systemic Toxicities Associated with Single Agent and Combination Therapies
Anti-Tumor Efficacy of BA3011
